IDEXX Laboratories, Inc. (NASDAQ:IDXX) Holdings Lowered by Blair William & Co. IL

Blair William & Co. IL decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,105,014 shares of the company's stock after selling 60,555 shares during the period. IDEXX Laboratories comprises approximately 1.3% of Blair William & Co. IL's holdings, making the stock its 12th biggest holding. Blair William & Co. IL owned about 1.35% of IDEXX Laboratories worth $456,857,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cranbrook Wealth Management LLC increased its position in shares of IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after acquiring an additional 25 shares during the last quarter. Perigon Wealth Management LLC increased its holdings in IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after purchasing an additional 26 shares during the last quarter. Summit Trail Advisors LLC raised its position in shares of IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares in the last quarter. Brown Brothers Harriman & Co. boosted its stake in shares of IDEXX Laboratories by 4.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company's stock valued at $375,000 after buying an additional 31 shares during the last quarter. Finally, IFP Advisors Inc grew its position in shares of IDEXX Laboratories by 3.6% during the fourth quarter. IFP Advisors Inc now owns 903 shares of the company's stock worth $373,000 after buying an additional 31 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of research analyst reports. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Morgan Stanley cut their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Finally, Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Stock Performance

IDXX stock traded down $0.73 during mid-day trading on Monday, reaching $415.15. The company had a trading volume of 236,374 shares, compared to its average volume of 580,565. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The stock has a market capitalization of $33.65 billion, a P/E ratio of 38.93, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock's 50-day simple moving average is $437.07 and its two-hundred day simple moving average is $442.57.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.